Theravance Biopharma Inc (TBPH)
8.97
-0.15
(-1.64%)
USD |
NASDAQ |
May 22, 16:00
8.97
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Cash from Financing (Quarterly): -1.716M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.716M |
| December 31, 2023 | -30.61M |
| September 30, 2023 | -31.40M |
| June 30, 2023 | -80.68M |
| March 31, 2023 | -56.24M |
| December 31, 2022 | -35.47M |
| September 30, 2022 | -722.03M |
| June 30, 2022 | 0.14M |
| March 31, 2022 | -1.448M |
| December 31, 2021 | 0.149M |
| September 30, 2021 | -2.286M |
| June 30, 2021 | 105.28M |
| March 31, 2021 | -11.29M |
| December 31, 2020 | 0.743M |
| September 30, 2020 | -0.963M |
| June 30, 2020 | 1.873M |
| March 31, 2020 | 261.43M |
| December 31, 2019 | -1.544M |
| September 30, 2019 | -0.134M |
| June 30, 2019 | 4.402M |
| March 31, 2019 | -1.433M |
| December 31, 2018 | 229.60M |
| September 30, 2018 | -0.322M |
| Date | Value |
|---|---|
| June 30, 2018 | -2.402M |
| March 31, 2018 | -1.68M |
| December 31, 2017 | 0.631M |
| September 30, 2017 | -0.789M |
| June 30, 2017 | 3.03M |
| March 31, 2017 | -1.216M |
| December 31, 2016 | 332.46M |
| September 30, 2016 | 0.481M |
| June 30, 2016 | 120.27M |
| March 31, 2016 | 26.02M |
| December 31, 2015 | 53.84M |
| September 30, 2015 | -0.082M |
| June 30, 2015 | 1.506M |
| March 31, 2015 | 26.04M |
| December 31, 2014 | -0.158M |
| September 30, 2014 | 0.262M |
| June 30, 2014 | 324.10M |
| March 31, 2014 | 46.42M |
| December 31, 2013 | 36.25M |
| September 30, 2013 | 33.17M |
| June 30, 2013 | 25.04M |
| March 31, 2013 | 29.13M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-722.03M
Minimum
Sep 2022
261.43M
Maximum
Mar 2020
-30.09M
Average
-1.496M
Median
Cash from Financing (Quarterly) Benchmarks
| Corcept Therapeutics Inc | -0.543M |
| Nektar Therapeutics | 42.00M |
| Stereotaxis Inc | 0.03M |
| Vanda Pharmaceuticals Inc | -- |
| Fate Therapeutics Inc | 95.49M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.022M |
| Cash from Investing (Quarterly) | 17.03M |
| Free Cash Flow | -18.44M |
| Free Cash Flow Per Share (Quarterly) | -0.0231 |
| Free Cash Flow to Equity (Quarterly) | -1.113M |
| Free Cash Flow to Firm (Quarterly) | -1.113M |
| Free Cash Flow Yield | -3.98% |